Szilvassy S J, Meyerrose T E, Ragland P L, Grimes B
Blood and Marrow Transplant Program, Lucille P. Markey Cancer Center, University of Kentucky, Lexington 40536-0093, USA.
Exp Hematol. 2001 Dec;29(12):1494-502. doi: 10.1016/s0301-472x(01)00751-2.
Hematopoietic progenitors generated by ex vivo expansion "home" less efficiently to the bone marrow (BM) after intravenous transplantation than fresh cells. To explore the underlying cause of this transplantation defect, we examined the homing and engraftment properties in vivo of fresh and cultured marrow cells differing in beta1 integrin expression.
Fresh murine BM cells, or the expanded progeny of enriched Sca-1(+) c-kit(+)Lin(-) stem cells, were fractionated into beta1(-/lo) and beta1(+) subpopulations by cell sorting. These populations were assayed for their content of in vitro colony-forming cells (CFCs), cells able to provide radioprotection, and early and long-term multilineage hematopoietic reconstitution following transplantation into myeloablated recipients. These endpoints were correlated with the homing properties of beta1(-/lo) and beta1(+) cells that were labeled with 5- (and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE) and tracked to hematopoietic organs 24 hours after injection into lethally irradiated mice.
Most normal stem and progenitor cells express high levels of beta1 integrin. In contrast, most clonogenic cells generated in vitro are beta1(-/lo). Consequently, expanded beta1(-/lo) progenitors failed to provide radioprotection or repopulate the hematopoietic system following intravenous transplantation. Defective engraftment of expanded cells was associated with reduced homing of beta1(-/lo) cells to the bone marrow.
Downregulation of beta1 integrin on primitive hematopoietic cells during ex vivo expansion reduces their homing efficiency and negatively impacts hematopoietic reconstitution in vivo. Strategies directed at preserving beta1 integrin expression during culture may improve the clinical utility of expanded hematopoietic cells.
经体外扩增产生的造血祖细胞经静脉移植后归巢至骨髓(BM)的效率低于新鲜细胞。为探究这种移植缺陷的潜在原因,我们检测了β1整合素表达不同的新鲜和培养骨髓细胞在体内的归巢和植入特性。
将新鲜小鼠骨髓细胞或富集的Sca-1(+) c-kit(+)Lin(-)干细胞的扩增后代通过细胞分选分为β1(-/lo)和β1(+)亚群。检测这些亚群的体外集落形成细胞(CFC)含量、能够提供辐射防护的细胞以及移植到骨髓清除受体后早期和长期多谱系造血重建情况。这些终点指标与用5-(和6-)羧基荧光素二乙酸琥珀酰亚胺酯(CFSE)标记的β1(-/lo)和β1(+)细胞的归巢特性相关,并在注射到致死性照射小鼠后24小时追踪至造血器官。
大多数正常干细胞和祖细胞表达高水平的β1整合素。相比之下,体外产生的大多数克隆形成细胞为β1(-/lo)。因此,扩增的β1(-/lo)祖细胞经静脉移植后未能提供辐射防护或重建造血系统。扩增细胞植入缺陷与β1(-/lo)细胞归巢至骨髓减少有关。
体外扩增过程中原始造血细胞上β1整合素的下调降低了它们的归巢效率,并对体内造血重建产生负面影响。旨在培养过程中保留β1整合素表达的策略可能会提高扩增造血细胞的临床应用价值。